Form 4: Equillium COO Executes Planned Stock Option Exercises

Equillium, Inc. Senior Vice President and COO Christine Zedelmayer exercised stock options and sold shares under a Rule 10b5-1 trading plan.

Summary

• Christine Zedelmayer, Senior Vice President and COO of Equillium, Inc., exercised options to acquire 115,833 shares of common stock.
• The exercise prices for these options ranged from $0.73 to $0.785 per share.
• Following the exercises, the reporting person sold a total of 95,833 shares at prices ranging from $2.70 to $3.04 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 27, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-planned 10b5-1 arrangement, which is standard for executive liquidity.

Positives

• The executive maintains a significant remaining beneficial ownership of 62,586 shares of common stock.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Future share price volatility may impact the value of remaining unexercised options.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice in the biotechnology sector for liquidity management and is generally viewed as neutral by institutional investors when pre-planned.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while avoiding allegations of insider trading.
• The exercise and sell-to-cover or sell-for-liquidity behavior is consistent with typical executive compensation cycles in small-cap biotech firms.

Stakeholder Impact

• Shareholders should note the reduction in direct insider holdings, though the volume is limited and pre-planned.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Equillium, EQ, Insider Trading, Form 4, Stock Options, Biotech, Executive Compensation